Astrazeneca (AZN) Return on Capital Employed (2009 - 2026)

Astrazeneca (AZN) has reported Return on Capital Employed for 18 consecutive years, with 9.76% the latest figure, recorded in Q1 2026.

• In Q1 2026, Return on Capital Employed rose 190.0% year-over-year to 9.76%; the TTM figure through Mar 2026 stood at 9.76% (up 190.0% YoY), while the FY2025 annual figure was 9.84%, down 3131.0% from the prior year.
• Return on Capital Employed came in at 9.76% for Q1 2026 at Astrazeneca, up from 9.49% in the prior quarter.
• The five-year high for Return on Capital Employed was 46.4% in Q4 2023, with the low at 0.46% in Q2 2022.
• Average Return on Capital Employed over 5 years is 8.94%, with a median of 7.05% recorded in 2024.
• Across the five-year window, Return on Capital Employed jumped 4096 bps in 2023 and sank 3334 bps in 2024, its largest moves.
• Year by year, Return on Capital Employed stood at 5.44% in 2022, then surged by 753 bps to 46.4% in 2023, then sank by 72 bps to 13.06% in 2024, then dropped by 27 bps to 9.49% in 2025, then increased by 3 bps to 9.76% in 2026.
• According to Business Quant data, Return on Capital Employed over the past three periods registered 9.76%, 9.49%, and 8.68% for Q1 2026, Q4 2025, and Q3 2025 respectively.